Labcorp Holdings saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 69 to 72.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating measures market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Over 100 years of market history shows that the best stocks typically have an RS Rating of above 80 in the early stages of their moves. See if Labcorp Holdings can continue to rebound and clear that threshold.
Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buying range in heavy trade.
Earnings grew 10% last quarter, up from 4% in the prior report. Revenue also increased, from 5% to 10%.
The company holds the No. 8 rank among its peers in the Medical-Services industry group. Hims & Hers Health, GeneDx Holdings and Progyny are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
